207 related articles for article (PubMed ID: 18582378)
41. Lower mRNA and protein expression levels of LC3 and Beclin1, markers of autophagy, were correlated with progression of renal clear cell carcinoma.
Deng Q; Wang Z; Wang L; Zhang L; Xiang X; Wang Z; Chong T
Jpn J Clin Oncol; 2013 Dec; 43(12):1261-8. PubMed ID: 24186908
[TBL] [Abstract][Full Text] [Related]
42. Expression and prognostic significance of fatty acid synthase in clear cell renal cell carcinoma.
Yuan Y; Yang X; Li Y; Liu Q; Wu F; Qu H; Gao H; Ge J; Xu Y; Wang H; Wang Y; Zhao Z
Pathol Res Pract; 2020 Nov; 216(11):153227. PubMed ID: 33027752
[TBL] [Abstract][Full Text] [Related]
43. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia.
Currie MJ; Gunningham SP; Turner K; Han C; Scott PA; Robinson BA; Chong W; Harris AL; Fox SB
J Pathol; 2002 Dec; 198(4):502-10. PubMed ID: 12434420
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA‑302a suppresses cell proliferation, migration and invasion in osteosarcoma by targeting ADAM9.
Yang X; Cui Y; Yang F; Sun C; Gao X
Mol Med Rep; 2017 Sep; 16(3):3565-3572. PubMed ID: 28713950
[TBL] [Abstract][Full Text] [Related]
45. Aberrant expression of ADAM9 in ovarian cancer and its clinical significance.
Guo T; Yuan D; Lin M; Zhu D; Xu N; Wang J
J Clin Lab Anal; 2020 Apr; 34(4):e23136. PubMed ID: 31793719
[TBL] [Abstract][Full Text] [Related]
46. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma.
Grützmann R; Lüttges J; Sipos B; Ammerpohl O; Dobrowolski F; Alldinger I; Kersting S; Ockert D; Koch R; Kalthoff H; Schackert HK; Saeger HD; Klöppel G; Pilarsky C
Br J Cancer; 2004 Mar; 90(5):1053-8. PubMed ID: 14997207
[TBL] [Abstract][Full Text] [Related]
47. Genome wide analysis of chromosomal alterations in oral squamous cell carcinomas revealed over expression of MGAM and ADAM9.
Vincent-Chong VK; Anwar A; Karen-Ng LP; Cheong SC; Yang YH; Pradeep PJ; Rahman ZA; Ismail SM; Zaini ZM; Prepageran N; Kallarakkal TG; Ramanathan A; Mohayadi NA; Rosli NS; Mustafa WM; Abraham MT; Tay KK; Zain RB
PLoS One; 2013; 8(2):e54705. PubMed ID: 23405089
[TBL] [Abstract][Full Text] [Related]
48. ADAM12 and ADAM17 gene expression in laser-capture microdissected and non-microdissected breast tumors.
Narita D; Seclaman E; Ilina R; Cireap N; Ursoniu S; Anghel A
Pathol Oncol Res; 2011 Jun; 17(2):375-85. PubMed ID: 21240579
[TBL] [Abstract][Full Text] [Related]
49. Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas.
Hemmerlein B; Galuschka L; Putzer N; Zischkau S; Heuser M
Histopathology; 2004 Dec; 45(6):603-11. PubMed ID: 15569051
[TBL] [Abstract][Full Text] [Related]
50. Alteration of apoptotic regulatory molecules expression during carcinogenesis and tumor progression of renal cell carcinoma.
Sejima T; Isoyama T; Miyagawa I
Int J Urol; 2003 Sep; 10(9):476-84. PubMed ID: 12941126
[TBL] [Abstract][Full Text] [Related]
51. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
52. Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma.
Ljungberg B; Jacobsen J; Häggström-Rudolfssson S; Rasmuson T; Lindh G; Grankvist K
Urol Res; 2003 Oct; 31(5):335-40. PubMed ID: 14574539
[TBL] [Abstract][Full Text] [Related]
53. Glutathione S-transferases as molecular markers of tumour progression and prognosis in renal cell carcinoma.
Searchfield L; Price SA; Betton G; Jasani B; Riccardi D; Griffiths DF
Histopathology; 2011 Jan; 58(2):180-90. PubMed ID: 21255063
[TBL] [Abstract][Full Text] [Related]
54. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
[TBL] [Abstract][Full Text] [Related]
55. Reduced expression of growth and differentiation factor-9 (GDF9) is associated with aggressive behaviour of human clear-cell renal cell carcinoma and poor patient survival.
Du P; Ye L; Yang Y; Jiang WG
Anticancer Res; 2014 Nov; 34(11):6515-20. PubMed ID: 25368253
[TBL] [Abstract][Full Text] [Related]
56. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma.
Campbell L; Gumbleton M; Griffiths DF
Br J Cancer; 2003 Nov; 89(10):1909-13. PubMed ID: 14612902
[TBL] [Abstract][Full Text] [Related]
57. Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells.
Blanchot-Jossic F; Jarry A; Masson D; Bach-Ngohou K; Paineau J; Denis MG; Laboisse CL; Mosnier JF
J Pathol; 2005 Oct; 207(2):156-63. PubMed ID: 16041691
[TBL] [Abstract][Full Text] [Related]
58. Decreased SPTLC1 expression predicts worse outcomes in ccRCC patients.
Zhu WK; Xu WH; Wang J; Huang YQ; Abudurexiti M; Qu YY; Zhu YP; Zhang HL; Ye DW
J Cell Biochem; 2020 Feb; 121(2):1552-1562. PubMed ID: 31512789
[TBL] [Abstract][Full Text] [Related]
59. Nuclear expression and clinical significance of phosphohistidine phosphatase 1 in clear-cell renal cell carcinoma.
Shen H; Yang P; Liu Q; Tian Y
J Int Med Res; 2015 Dec; 43(6):747-57. PubMed ID: 26537769
[TBL] [Abstract][Full Text] [Related]
60. Up-regulation of SR-BI promotes progression and serves as a prognostic biomarker in clear cell renal cell carcinoma.
Xu GH; Lou N; Shi HC; Xu YC; Ruan HL; Xiao W; Liu L; Li X; Xiao HB; Qiu B; Bao L; Yuan CF; Zhou YL; Hu WJ; Chen K; Yang HM; Zhang XP
BMC Cancer; 2018 Jan; 18(1):88. PubMed ID: 29357836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
